Role of p53 in the inhibitory effects of interferon-α subtypes on proliferation of hepatocellular carcinoma cells

Biomedical Research

Volumn 27, Issue 5, 2006, Pages 219-226

  Fujioka, Noboru ^a   Ariyasu, Toshio ^a   Arai, Norie ^a   Ariyasu, Harumi ^a   Yamamoto, Shigeto ^a   Tanimoto, Tadao ^a   Ikegami, Hakuo ^a   Ikeda, Masao ^a   Ohta, Tsunetaka ^a   Fukuda, Shigeharu ^a   Kurimoto, Masashi ^a  

^a HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA1 INTERFERON; ALPHA10 INTERFERON; ALPHA2 INTERFERON; ALPHA5 INTERFERON; ALPHA8 INTERFERON; ANTINEOPLASTIC AGENT; FLUOROURACIL; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33751104441     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.27.219     Document Type: Article

References (28)

1. Ariyasu T, Fujioka N, Yamamoto S, Yanai Y, Yamauchi H, Ikegami H, Ikeda M, Kurimoto M, Horie S and Kitamura T (2004) Correlation between interferon alpha subtypes in human renal carcinoma cell lines. Cancer Genomics Proteomics 1, 87-94.
2. Ariyasu T, Tanaka T, Fujioka N, Yanai Y, Yamamoto S, Yamauchi H, Ikegami H, Ikeda M and Kurimoto M (2005) Effects of interferon-alpha subtypes on Th1/Th2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders. In vitro Cell Dev Biol Anim 41, 50-56.
3. Benoit P, Maguire D, Plavec I, Kocher H, Tovey M and Meyer R (1993) A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. J Immunol 150, 707-716.
4. 315 stimulates p53-dependent transcription. J Biol Chem 276, 4699-4708.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram program quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
6. Domanski P, Witte M, Kellum M, Rubinstein M, Hakett R, Pitha P and Colamonici OR (1995) Cloning and expression of a long form of the β subunit of the interferon αβ receptor that is required for signaling. J Biol Chem 270, 21606-21611.
7. Fish EN, Banerjee K and Stebbing N (1989) The role of three domains in the biological activity of human interferon-alpha. J Interferon Res 9, 97-114.
8. Foster GR, Masri SH, David R, Jones M, Datta A, Lombardi G, Runkell L, De Dios C, Sizing I, James MJ and Marelli-Berg FM (2004) IFN-α subtypes differentially affect human T cell motility. J Immunol 173, 1663-1670.
9. Fujioka N, Tanaka T, Ariyasu T, Yanai Y, Yamamoto S, Yamauchi H, Ikegami H, Ikeda M, Orita K and Kurimoto M (2004) In vitro effects of interferon-alpha subtypes on Th1/Th2 balance in the peripheral blood mononuclear cells from patients with hepatitis C virus infection. Biomed Res 25, 75-82.
10. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H and Kawanishi M (1999) Effects of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29, 1124-1130.
11. Jacks T and Weinberg RA (1996) Cell-cycle control and its watchman. Nature 381, 643-644.
12. Kim C, Koike K, Saito I, Miyamura T and Jay G (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351, 317-320.
13. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T and Koike K (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4, 1065-1067.
14. North AJ, Galazkiewicz B, Byers TJ, Glenney JR Jr and Small JV (1993) Complementary distributirtion of vinculin and dystrophin define two distinct sarcolemma domains in smooth muscle. J Cell Biol 120, 1159-1167.
15. Novick D, Cohen B and Rubinstein M (1994) The human interferon alpha/ beta receptor: characterization and molecular cloning. Cell 77, 391-400.
16. Okita K, Sakaida I and Hino K (2002) Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 62, 24-28.
17. Okuda K (2000) Hepatocellular carcinoma. J Hepatol 32, 225-237.
18. Prives C and Hall PA (1999) The p53 pathway. J Pathol 187, 112-126.
19. Poynard T, Bedossa P and Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC group. Lancet 349, 825-832.
20. Schafer DF and Sorrell MF (1999) Hepatocellular carcinoma. Lancet 353, 1253-1257.
21. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K and Taniguchi T (2003) Integration of interferon-α/β signaling to p53 responses in tumor suppression and antiviral defence. Nature 424, 516-523.
22. Vilcek J (2003) Boosting p53 with interferon and viruses. Nat Immunol 4, 825-826.
23. Vogelstein B, Lane D and Levine AJ (2000) Surfing the p53 network. Nature 408, 307-310.
24. Vousden KH and Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2, 594-604.
25. Yamamoto T, Kojima S, Ichi S, Kashiwazaki Y, Koide T and Sokawa Y (1999) Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi burkitt's lymphoma cells. J Interferon Cytokine Res 19, 1343-1349.
26. Yanai Y, Horie S, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M and Kitamura T (2001) Characterization of the antitumor activities of IFN-α8 on renal cell carcinoma cells in vivo. J Interferon Cytokine Res 21, 1129-1136.
27. Yanai Y, Sinou O, Kayano T, Ariyasu H, Yamamoto K, Yamauchi H, Ikegami H and Kurimoto M (2001) Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions. J Interferon Cytokine Res 21, 835-841.
28. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G and Omata M (1999) Interferon therapy reduces the risk for hepatocellular carcinoma development: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131, 174-181.